文献速递产科母胎医学

重度妊娠期高血压疾病产后布洛芬随机试验

A randomized trial of postpartum ibuprofen in severe hypertensive disorders of pregnancy.
PubMed 文献 · Am J Obstet Gynecol · 2025-02-11

这项随机双盲试验将140例重度妊娠期高血压疾病患者产后随机分配至布洛芬600 mg或对乙酰氨基酚650 mg(对照)每6小时一次,主要结局产后住院期间重度高血压发生率布洛芬组38.6% vs 对照组41.4%,绝对差2.8个百分点(95%CI -13.1%至18.5%,P=.73)。结论认为布洛芬未增加产后重度高血压发生率,支持该类患者产后使用布洛芬。

要点

  • 产后重度高血压发生率布洛芬组38.6% vs 对乙酰氨基酚组41.4%,无显著差异(P=.73)。
  • 降压药使用率布洛芬组35.7% vs 对照组40.0%(P=.60),无差异。
  • 产后平均动脉压布洛芬组95.7±8.2 vs 对照组95.9±9.5(P=.91),无差异。

核心结论

  • 在重度妊娠期高血压疾病患者中,产后使用布洛芬未增加产后重度高血压的发生率。
  • 布洛芬未影响其他血压结局、疼痛控制或患者满意度。
  • 这些发现支持重度妊娠期高血压疾病患者产后使用布洛芬。

研究设计与样本

  • 随机双盲试验,纳入重度妊娠期高血压疾病伴重度高血压患者。
  • 产后镇痛方案随机分为布洛芬600 mg组或对乙酰氨基酚650 mg(对照)组,每6小时一次。
  • 主要结局为产后住院期间重度高血压。
  • 检测产后重度高血压35%差异所需样本量为132。
  • 2017年1月至2019年10月共纳入140例参与者。

主要发现

  • 产后重度高血压发生率布洛芬组38.6% vs 对照组41.4%,绝对差2.8个百分点(95%CI -13.1%至18.5%,P=.73)。
  • 降压药使用率布洛芬组35.7% vs 对照组40.0%(P=.60)。
  • 产后平均动脉压布洛芬组95.7±8.2 vs 对照组95.9±9.5(P=.91)。
  • 门诊血压、患者满意度、利尿和疼痛控制指标两组相似。

临床怎么用

  • 作者结论认为这些发现支持重度妊娠期高血压疾病患者产后使用布洛芬。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ibuprofen has been shown to increase blood pressure in nonpregnant adults with hypertension, but its impact on blood pressure when used for postpartum analgesia in patients with a hypertensive disorder of pregnancy is less clear, particularly for those with severe hypertension. OBJECTIVE: To evaluate the impact of ibuprofen on postpartum blood pressure outcomes in patients with hypertensive disorders of pregnancy with severe hypertension. STUDY DESIGN: In this randomized, double-blind trial, we randomly assigned patients with hypertensive disorders of pregnancy with severe hypertension to receive a postpartum analgesic regimen consisting of either ibuprofen 600 mg or acetaminophen 650 mg (control) every 6 hours. The primary outcome was severe hypertension during postpartum hospitalization. Secondary outcomes included other measures of blood pressure control such as antihypertensive medication use and average postpartum mean arterial pressure, and outpatient blood pressure as well as patient satisfaction, pain control, and diuresis. A sample size of 132 was needed to detect a 35% difference in severe postpartum hypertension. RESULTS: We enrolled 140 participants from January 2017-October 2019. The prevalence of severe hypertension postpartum did not differ between participants receiving ibuprofen (38.6%) vs control (41.4%); the absolute difference was 2.8 percentage points, 95% confidence interval -13.1% to 18.5%, P=.73. There was no difference between the ibuprofen and control groups for antihypertensive medication use (35.7% vs 40.0%, P=.60) or average postpartum mean arterial pressure (95.7 ± 8.2 vs 95.9 ± 9.5, P=.91, respectively). Measures of outpatient blood pressure, patient satisfaction, diuresis, and pain control were also similar. CONCLUSION: In patients with hypertensive disorders of pregnancy with severe hypertension, use of ibuprofen postpartum did not increase the prevalence of postpartum severe hypertension. Ibuprofen use did not impact other blood pressure outcomes, pain control, or patient satisfaction. These findings support ibuprofen use during the postpartum period in patients with hypertensive disorders of pregnancy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Penfield CA, Oakes MC, Caballero D, et al. A randomized trial of postpartum ibuprofen in severe hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2025. PMID: 39938855. doi:10.1016/j.ajog.2025.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。